



Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com
CIN. : L74899DL1978PLC009181



June 29, 2026

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Subject: Jagsonpal Pharmaceuticals to acquire 85% stake in Aequitas Healthcare Private Limited
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015 – Acquisition**

Dear Sir/ Madam,

We wish to inform you that the Company has entered into a Share Purchase Agreement (SPA) to acquire 85% of the paid up equity share capital of Aequitas Healthcare Private Limited (CIN:U36994MH2017PTC299446) (Target Company), which is engaged in the sale and distribution of pharmaceutical products to hospitals.

The proposed acquisition is subject to fulfilment of the conditions in the SPA.

The detailed disclosure as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 updated as on January 30, 2026 are enclosed herewith as **Annexure-A**.

A press release being issued by the Company in this regard is attached as **Annexure -B**.

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

Pratham Rawal
Company Secretary & Compliance office



Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com

CIN. : L74899DL1978PLC009181



Annexure-A

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III of the Listing Regulations read with SEBI master circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 updaed as on January 30, 2026:

Sr. No.	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	Aequitas Healthcare Private Limited, a company incorporated in India under the provisions of the Companies Act, 2013, having its registered address at 305, Plot 119/120, Jaisingh Business Centre, 3rd Floor, Sahar Road, Andheri East, Mumbai, Maharashtra, India- 400099 and bearing CIN: U36994MH2017PTC299446. The revenue from operations for FY 2025-26 was INR 53.31 crores.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The acquisition does not fall within related party transactions. The promoter/promoter group of the Company have no interest in Aequitas Healthcare Private Limited.
c)	Industry to which the entity being acquired belongs	Pharmaceuticals and Healthcare
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This acquisition aligns with the Company's strategic objective of gaining access to the hospital channel and institutional doctor network for the Company's products, significantly reducing the time required to build these relationships organically.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	No governmental or regulatory approvals are required for the proposed acquisition.
f)	Indicative time period for completion of the acquisition	Expected to be completed by 15th July 2026
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
h)	Cost of acquisition or the price at which the shares are acquired	Cash consideration aggregating INR- 20.8 Crore for 85% stake
i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	Company will initially acquire 85% of the paid up equity share capital of the Target Company.



Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Aequitas Healthcare Private Limited is a 8-year-old pharmaceutical company headquartered in Mumbai, operating pre-dominantly in sales of pharmaceutical products to hospitals.</p> <p>Aequitas was incorporated on 07/09/2017.</p> <p>The revenue from operations for previous three years is as follows,</p> <table border="1" data-bbox="808 642 1386 869"> <thead> <tr> <th>FY</th> <th>Turnover (in INR Crores)</th> </tr> </thead> <tbody> <tr> <td>2025-26</td> <td>53.31</td> </tr> <tr> <td>2024-25</td> <td>56.19</td> </tr> <tr> <td>2023-24</td> <td>53.71</td> </tr> </tbody> </table> <p>Countries in which Aequitas has presence: India</p>	FY	Turnover (in INR Crores)	2025-26	53.31	2024-25	56.19	2023-24	53.71
FY	Turnover (in INR Crores)									
2025-26	53.31									
2024-25	56.19									
2023-24	53.71									



Jagsonpal Pharmaceuticals to acquire 85% stake in Aequitas Healthcare Transaction marks its strategic entry in the Hospital segment

Gurugram, India | June 29, 2026 – Jagsonpal Pharmaceuticals Ltd. (Jagsonpal) today announced that it has entered into a definitive Agreement for the acquisition of 85% equity stake in Aequitas Healthcare Private Limited ("Aequitas"), a Mumbai-based pharmaceutical company primarily focused on sale and distribution of pharmaceutical products to hospitals.

The proposed acquisition marks Jagsonpal's strategic entry into the hospital segment and is aligned with the Company's long-term vision of strengthening its presence in India's growing healthcare ecosystem.

Founded in 2017, Aequitas has a robust business covering all leading hospital chains in India. The company had revenues of Rs. 53 crores in FY26

The total consideration for 85% stake would be Rs. 20.8 crores, which shall be funded from internal accruals of Jagsonpal. The current Directors of Aequitas shall retain 15% stake and shall continue to be associated with the business.

Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: *"The proposed acquisition of Aequitas represents an important strategic milestone for Jagsonpal. It provides us with a ready platform for a meaningful presence in the hospital segment, which now contributes ~10% of pharma industry sales and growing faster. We strongly believe that Jagsonpal's portfolio of established brands will greatly benefit from Aequitas' strong institutional relationships, delivering sustainable long-term value to our shareholders."*

Mr. Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: *"This transaction is a structurally transformative pivot that moves Jagsonpal from a legacy retail prescription player to Omnichannel Specialty healthcare business in India and is reflective of our long-term commitment to building scalable, high-quality healthcare delivery in India. We look forward to unlocking value through operational excellence, disciplined execution, and patient-centric growth."*

Mr. Shailesh Kamat, Director and largest shareholder at Aequitas said: *"In a short span of 8 years, we have built a strong hospital business with a quality portfolio, deep institutional relationships and a committed team. We are pleased to associate with Jagsonpal Pharmaceuticals, whose proven track record of building healthcare brands and scaling businesses makes us well positioned to take Aequitas to its next phase of growth. We believe this partnership will unlock new opportunities for our employees, customers & stakeholders and deeply benefit the healthcare ecosystem."*

The transaction is subject to the fulfilment of customary closing conditions, and expected to be concluded by 15th July, 2026.

J Sagar & Associates were the legal Advisors to Jagsonpal while Noverra Partners advised Aequitas on the transaction.

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over five decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, and Dermatology segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: www.jagsonpal.com

Company contact	Investor Relations Team
Email: cs@jagsonpal.com , Tel: +91 124 4406710 Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 Corporate Office: Nimai Tower, 3 rd floor, Udyog Vihar, Gurugram, Haryana – 122015	Soumya Chhajed Email- soumya@goindiaadvisors.com Mobile: +91-8619707750